Medtronic has announced the US launch of the Solitaire X Revascularisation Device, and its first use in patients for the treatment of acute ischaemic stroke.
For ten years, the industry-leading Solitaire Revascularisation Device has enabled physicians in helping patients have a better chance at recovering from stroke. Solitaire X is a fourth generation device featuring an optimised delivery system for improved efficiency—while retaining the technical features that have made the Solitaire family of revascularisation devices clinically proven and highly effective. In addition, Medtronic introduces Phenom 21 Catheter, a 160cm length microcatheter for the delivery of all sizes of Solitaire X.
The Solitaire X device mechanically removes blood clots from blocked vessels in the brain to restore blood flow in patients suffering an acute ischaemic stroke with large vessel occlusion. When combined with Phenom 21, Solitaire X provides a low clot crossing profile, with smooth delivery to occlusions in distal vessels as small as 2mm.
“Medtronic continues to deliver technological innovations to advance stroke treatment. As a long-time Solitaire user, I am impressed with the ease of the Solitaire X delivery,” said Reza Jahan, professor of radiology and neurosurgery at UCLA. “I find that Solitaire X 6×40 device combined with Phenom 21 catheter provides smooth navigation especially when working with complicated anatomy.”
“Our commitment to enable physicians to improve outcomes for stroke patients worldwide will always be our motivation,” said Stacey Pugh, vice president and general manager of Medtronic’s Neurovascular business. “The net result of that commitment is the launch of a 4th generation device—Solitaire X—which marks 10 years of innovation in stroke therapy.”
